Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2
Graphical abstract
Electrostatic surface representation of NQO2 with NSC660841 docked in the binding pocked. NSC660841 is identified as the most potent inhibitor of NQO2 yet reported (IC50 = 6 nM).
Section snippets
Acknowledgements
This work was supported by an MRC programme grant to I.J.S. (G0500366) and a project grant from AICR (I.J.S., R.B. and K.A.N.). We thank the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI, for the supply of the imidazoacridin-6-ones used in this work. Professor Nicola Tirelli is thanked for providing the facilities to carry out the DNA binding analysis. Dr. Roger Whitehead and Mr. John Barnes are thanked for providing the
References and notes (28)
- et al.
Biochem. Biophys. Acta
(1957) - et al.
Biochem. Biophys. Res. Commun.
(1961) - et al.
Mol. Cell.
(2005) - et al.
J. Biol. Chem.
(2006) - et al.
Bioorg. Med. Chem. Lett.
(2006) - et al.
Bioorg. Med. Chem.
(2010) - et al.
J. Biochem. Pharmacol.
(2002) - et al.
Int. J. Radiat. Oncol.
(1989) - et al.
Biochem. Pharmacol.
(2005) - et al.
Blood
(2007)
J. Biol.
Gene Dev.
Cancer Res.
Cancer Res.
Cited by (19)
Quinone Reductases
2018, Comprehensive Toxicology: Third EditionTargeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells
2015, Biochemical PharmacologyCitation Excerpt :The drug is an unusual topoisomerase II inhibitor [14], that also intercalates to DNA, and following metabolic activation covalently crosslinks DNA strands [15–17]. Additionally, C-1311 effectively decreases tumor angiogenesis by down-regulating hypoxia-inducible factor-1 α (HIF-1α)/vascular endothelial growth factor (VEGF) pathway [18], and blocks quinone oxidoreductase NQO2 [19]. The drug is particularly active against leukemia [20], colon [15], lung [21], bladder [22], ovarian and osteogenic sarcoma cell lines [23].
On the preferred structure of dicoumarol and implications for enzyme binding: A quantum chemical analysis
2014, Chemical Physics LettersCitation Excerpt :Interestingly, coumarin was chosen as a probe druglike molecule for computational studies of transport across a lipid membrane using molecular dynamics simulations [3]. Recently, we have sought to identify and develop inhibitors of two oxidoreductases linked to cancer, NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2) [4–9]. For NQO1, which is overexpressed in some solid tumours [10], we have identified coumarin scaffolds as having inhibitory activity [6,7].
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2)
2010, Bioorganic and Medicinal Chemistry LettersIdentification and pharmacokinetics of quinone reductase 2 inhibitors after oral administration of garcinia mangostana L. extract in rat by LC-MS/MS
2020, Journal of Agricultural and Food Chemistry